

Attorney Docket: 1830/50520
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MASAHIRO IMOTO ET AL.

Serial No.: TBA

Group Art Unit:

Filed: Herewith

Examiner:

Title: HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING
NICOTINIC ACETYLCHOLINE ALFA4 BETA2 RECEPTOR

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.97 and 1.98

Commissioner for Patents
Washington, D.C. 20231

Sir:


In accordance with the duty of disclosure under 37 CFR \$1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem relevant to patentability of the claims of the above-identified application.

The present Information Disclosure Statement is being filed (1) no later than three months from the application's filing date or (2) before the mailing date of the first Office Action on the merits (whichever is later), and therefore no certification under 37 C.F.R. \$1.97(e) or fee under 37 C.F.R. \$1.17(p) is required.

10/009607

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,


Herbert I. Cantor

Registration No. 24,392

CROWELL & MORING, LLP
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844